Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | REN | P00797 | 9/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430907 | 0.92 | CTSS (0.39) | CTSLCTSSCTSKRENMMP8 | |
| SCHEMBL6081794 | 0.87 | CTSS (0.43) | CTSLCTSSCTSKPIN1WNT3A | |
| SCHEMBL6081796 | 0.87 | CTSS (0.43) | CTSLCTSSCTSKPIN1WNT3A | |
| SCHEMBL5415759 | 0.86 | REN (0.40) | CTSLCTSSCTSKRENPIN1 | |
| SCHEMBL5955890 | 0.86 | REN (0.40) | CTSLCTSSCTSKRENPIN1 | |
| SCHEMBL5955005 | 0.85 | REN (0.40) | CTSLCTSSCTSKREN | |
| SCHEMBL5955003 | 0.85 | REN (0.40) | CTSLCTSSCTSKREN | |
| SCHEMBL14563000 | 0.83 | CTSS (0.50) | CTSLCTSSCTSKMMP2MMP9 | |
| SCHEMBL5435509 | 0.83 | CTSS (0.53) | CTSLCTSSCTSKREN | |
| SCHEMBL5435501 | 0.83 | CTSS (0.53) | CTSLCTSSCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | claimed |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | US | claimed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | claimed |
| EP-1515726-A1 | MORPHOLINE AND TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | claimed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023132842-A1 | DRUG COMBINATION TO TREAT MICROBIAL INFECTIONS INCLUDING CORONAVIRUS | AiPharma Global Holdings LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | US | disclosed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1515726-A1 | MORPHOLINE AND TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSL 11/4885CTSS 1/4885CTSK 8/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | CTSL 13/4885CTSS 3/4885CTSK 11/4885 |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSL 11/4885CTSS 1/4885CTSK 8/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | CTSL 4020/4885CTSS 2981/4885CTSK 3125/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | CTSL 4020/4885CTSS 2981/4885CTSK 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.